Vista Pharmaceuticals MD, chairman, board of directors and AGM
BSE: 524711Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹5.48.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹36 Cr3,508th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 1.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- −28.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- −32.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.27
- Volume, BSEVolume. Shares traded on the last trading day.
- 6,933
Vista Pharmaceuticals board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Managing directorMURALI MERAGA
14 directors7 independent3 executive4 non-executive
- MALLEM HANUMANTHA RAONon-executive · joined Sep 1993 · reappointed Sep 2023 · 1 listed board · 1 committee seat
- DHANANJAYA ALLIExecutive · joined Sep 2015 · reappointed Sep 2025 · 1 listed board
- MURALI MERAGA · Managing directorExecutive · joined Oct 2022 · reappointed Sep 2025 · 1 listed board
- UMAKANTH KATTANon-executive · joined Jul 2020 · reappointed Sep 2023 · 1 listed board
- PAVAN SATHVIK GILAKAExecutive · joined Oct 2022 · reappointed Sep 2025 · 1 listed board
- STANLEY PRABHAKAR REDDYNon-executive · joined Aug 2016 · 1 listed board
- DIVAKAR REDDY YERRABOMMANAHALLINon-executive · joined Sep 2019 · reappointed Sep 2023 · 82 months as independent · 1 listed board · 1 as independent
- UMESH VIRUPAKAH BANAKARIndependent · joined Feb 2018 · reappointed Sep 2024 · 88 months as independent · 1 listed board · 1 as independent · 2 committee seats
- DIVYA BHAVANI CHAKRAVARTHULAIndependent · joined Feb 2018 · reappointed Sep 2024 · 88 months as independent · 1 listed board · 1 as independent · 2 committee seats, 2 as chair
- NAGA RAJA MADINENIIndependent · joined Oct 2023 · 33 months as independent · 1 listed board · 1 as independent
- MADHU SUDAN ANCHIIndependent · joined Oct 2023 · 33 months as independent · 1 listed board · 1 as independent
- SWAPNA PRIYA GUNDUBOINAIndependent · joined Oct 2023 · 33 months as independent · 1 listed board · 1 as independent
- ANUMALA RAVI CHANDRAKUMARIndependent · joined Oct 2023 · 33 months as independent · 1 listed board · 1 as independent · 1 committee seat
- RAMA MOHAN MANAMASAIndependent · joined Oct 2023 · 33 months as independent · 1 listed board · 1 as independent
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 29 May 202612 of 14 present7 independent · 104 days in between
- 13 Feb 202612 of 14 present7 independent
Audit Committee
Chair DIVYA BHAVANI CHAKRAVARTHULA
UMESH VIRUPAKAH BANAKAR, ANUMALA RAVI CHANDRAKUMAR
- 29 May 20263 of 3 present3 independent · 104 days in between
- 13 Feb 20263 of 3 present3 independent
Nomination and remuneration committee
Chair DIVYA BHAVANI CHAKRAVARTHULA
UMESH VIRUPAKAH BANAKAR, ANUMALA RAVI CHANDRAKUMAR
No meeting listed in the filing.
Stakeholders Relationship Committee
Chair DIVYA BHAVANI CHAKRAVARTHULA
UMESH VIRUPAKAH BANAKAR, ANUMALA RAVI CHANDRAKUMAR
- 29 May 20263 of 3 present3 independent · 104 days in between
- 13 Feb 20263 of 3 present3 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- A M REDDY & DR REDDYPeer-review certificate valid to Feb 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- No
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Sep 2025. The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Preferential IssuesMar 2025 | 12.30 | a. Working capital requirement; b. Repayment of Loans availed from Banks/ Financial Institution c. Expansion of business activities d. General corporate purposes. e. Investment in future projects | 12.30 | 12.30 | No |